The cytokine space is undergoing a transformative evolution, driven by relentless innovation and a renewed determination to overcome past challenges. With fresh strategies and cutting-edge advancements, world-class drug developers are redefining targeted cytokine delivery – unlocking new frontiers from Oncology to Immunology & Inflammation.
While early cytokine-based therapies paved the way for immunotherapy, clinical setbacks and scepticism have cast doubt on their full potential. However, the cytokine community has refused to be defined by past limitations. By addressing systemic toxicity, optimizing efficacy beyond single-cytokine approaches, and bridging the gap between preclinical success and clinical translation, the field is entering a new era of possibility and progress.
The 6th Cytokine-Based Drug Development Summit brings together the most influential leaders from Candel, Deka Biosciences, Regeneron, Sanofi, ModeX, OSE, and more to navigate the key challenges in specificity, toxicity, and efficacy – while exploring revolutionary therapeutic modalities, including pro-drug, pulsed, targeted, and multi-specific immunomodulation.
The future of cytokine-based therapies is within reach – join us as we push the boundaries of possibility and redefine success in immunotherapy!
2025 Cytokine Trailblazers Include:
“After decades of research into the potential of cytokines to elicit antitumor immune responses, checkpoint inhibition appears to have made room for a new coming of age for cytokine therapy. It’s exciting to see the development of new technologies that can more precisely leverage the power and beauty of cytokine biology in this new era of cancer immunotherapy.”
Bridget O’Keeffe
Vice President Clinical Development
“This meeting brings together leaders in cytokine biology, therapeutic design, and immune oncology to collectively advance the development of targeted and effective cancer drugs.”
Jamie Spangler
Assistant Professor
Johns Hopkins University
